CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 50 enrolled
Drug / intervention
Lansoprazole +1 moredrug
Likely dose
Lansoprazole 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01046253
NCT01046253Phase 1Completed
CompareCT.gov

A Relative Bioavailability Replicate Sprinkle Study of Lansoprazole 30 mg Delayed-Release Capsules Under Fasting Conditions

Teva Pharmaceuticals USA·interventional·Posted Jan 11, 2010·Updated Dec 8, 2010

In Brief

A Phase 1 clinical trial evaluating Lansoprazole and Prevacid® for Healthy. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The object of this study is to compare the relative bioavailability of lansoprazole 30 mg delayed-release capsules (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA Pharmaceuticals USA) with that of PREVACID® capsules (TAP Pharmaceuticals, Inc.) in healthy, adult, subjects under fasting conditions with dosing by applesauce-sprinkle method.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 11, 2010
Enrollment StartJan 1, 2004
Primary CompletionJan 1, 2004
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 16.5 years ago

Interventions

Lansoprazoledrug

30 mg Delayed-Release Capsules

Prevacid®drug

30 mg Delayed-Release Capsule